As the prevalence of obesity, type 2 diabetes, and the opioid crisis in the United States continues to rise, so does chronic liver disease. From hepatitis C and hepatitis B to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver disease affects a significant portion of the U.S. population. Hepatitis C virus (HCV) is a leading cause of cirrhosis, liver cancer, and mortality worldwide. Injection drug use, arising in conjunction with the opioid crisis, has contributed significantly to the increase in HCV infections. Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significantly increased morbidity and mortality. Furthermore, the rising number of obese and diabetic patients has resulted in the increased prevalence of NAFLD, which may progress to NASH in a large number of patients. To help clinicians and patients navigate the changing landscape of liver disease, we designed the Liver Disease Hub to provide resources and guidelines for screening, testing, and treatment of liver disease.
Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.
Getting Closer to Targeted Therapies for NASH: Are You Ready?
|
This CME Outfitters webcast will address these challenges in diagnosing and treating NASH. Expert faculty will advise on appropriate testing, current clinical algorithms, and results from relevant late-stage clinical trials. |
Creating Action Steps for Linking Underserved Populations with Hepatitis C Care
|
Hear expert insights on creating action steps to improve access to Hepatitis C care for patients within underserved populations in this upcoming CME Outfitters Live and OnDemand webcast. Expert faculty will discuss the many barriers to treating HCV in the injection drug use population, including stigma and established negative perceptions about people who inject drugs (PWID), with special attention paid to applying CDC universal screening guidelines to improve diagnosis and linkage to treatment, expanding treatment for HCV in primary care settings, and addressing disparities in HCV treatment initiation in underserved communities. |
Treatment Decisions for Patients with HCV and CKD
|
This CMEO BriefCase will introduce a complex HCV case involving a patient with HCV and chronic kidney disease (CKD). Join Drs. Nancy Reau and Anthony Martinez as they dive deeper into treatment and management considerations for such patients, focusing on screening, diagnosis, and risk factors as well as the epidemiology and shared pathobiology of HCV and CKD. |
Mitigating Progression of Liver Fibrosis in HIV/HCV Coinfection
|
This CMEO BriefCase will introduce a complex case involving treatment and management considerations for a patient with HIV and HCV. Join Drs. Nancy Reau and Christian Ramers as they explore the epidemiology and shared pathobiology of liver fibrosis in HIV/HCV, real-world data for available therapies, contraindicated agent combinations, and when and how to treat. |
Treatment Selection in a Patient with Decompensated Cirrhosis
|
This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Join our faculty experts as they delve into the epidemiology and shared pathobiology of HCV and decompensated cirrhosis, identify compensated versus decompensated cirrhosis, and discuss surveillance strategies for HCC. |
Resources for Clinicians
HCV
AASLD-IDSA Recommendations for Testing, Managing, and Treating HCV
CDC Recommended Testing Sequence for Identifying HCV
Guide to Comprehensive Hep C Counseling and Testing
HIV-HCV Coinfection
Clinician Guidance for Patients with HIV/HCV Coinfection
AHP
AHP Patient Education: Recommended Websites, Questions for Your Clinician
Resources for Patients
Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.